277,188 research outputs found
GLUCO SHIELD PRO
No full textAs others have stated, it isn't safe to assume they hate Gluco Shield Pro. I wish to spout something that provides a detailed explanation relative to Gluco Shield Pro. I don't need to make waves. My notion is based around my assumption that nobody has an idiosyncrasy about Gluco Shield Pro. It is clear to me this I cannot keep clear of it, at least partially. Actually, that is a generic Gluco Shield Pro that has a good bit of hype surrounding it. Alright, "Cleanliness is next to Godliness." You say Gluco Shield Pro, I say Gluco Shield Pro. Gluco Shield Pro is not one of the strategies I've mastered. We will resume with my engaging and witty ideas concerning Gluco Shield Pro
Systematic study of effect of cross-drafts and nozzle diameter on shield gas coverage
No full textA shield gas flow rate of 15–20 L min21 is typically specified in metal inert gas welding, but is often adjusted to as high as 36 L min21 by welders in practice. Not only is this overuse of shield gas wasteful, but uncontrolled high gas flows can lead to significant turbulence induced porosity in the final weld. There is therefore a need to understand and control the minimum shield gas flow rate used in practical welding where cross-drafts may affect the coverage. Very low gas coverage or no shielding leads to porosity and spatter development in the weld region. A systematic study is reported of the weld quality achieved for a range of shield gas flow rates, cross-draft speeds and nozzle diameters using optical visualisation and numerical modelling to determine the shield gas coverage. As a consequence of the study, the shield gas flow has been reduced to 12 L min21 in production welding, representing a significant process cost saving and reduced environmental impact with no compromise to the final weld quality
Did Blue Cross and Blue Shield Suffer from Adverse Selection? Evidence from the 1950s
No full textThis paper uses a unique data set from 1957 to examine whether or not Blue Cross and Blue Shield suffered from an adverse selection death spiral after for-profit commercial insurance companies entered the market for health insurance. Results suggest that moving to experience rating may have helped the Blues counteract adverse selection in the group health insurance market. Adverse selection posed a greater problem for the Blues in the market for individual health insurance, possibly because of differences in the way the Blues screened potential enrollees relative to commercial insurance companies.
No by heav'ns I exclaim'd may I perish if ever I plant in that bosom a Thorn [first line of chorus]
No full textstrophic with choruspiano and voice breastr to adornSonneck-Upton p. 428Johns Hopkins University, Levy Sheet Music Collection, Box
029, Item 030Composed by William Shield, Musician in Ordinary to His Majesty.Sung by Mr. Incledon at the Theatre Royal Covent Garde
SHIELD technology demonstrators
No full textSHIELD technology demonstrators have been conceived to illustrate the functionalities of specific security, privacy, and dependability (SPD) technologies that, being domain independent, might be adopted in several application scenarios. The selected technologies have been introduced in Chapter 3, while this chapter provides more detailed information on their usage from a wider perspective. SHIELD technology demonstrators consist of laboratory prototypes and experiments that allow to test and evaluate all the functionalities offered by a SPD technology, rather than focusing on the specific functionality subset used in the domains presented in the previous chapters
No by heav'ns I exclaim'd may I perish if ever I plant in that bosom a Thorn [first line of chorus]
No full textstrophic with choruspiano and voice breastr to adornSonneck-Upton p. 428Johns Hopkins University, Levy Sheet Music Collection, Box
029, Item 030Composed by William Shield, Musician in Ordinary to His Majesty.Sung by Mr. Incledon at the Theatre Royal Covent Garde
6q24 transient neonatal diabetes
No full textTransient Neonatal Diabetes (type 1) is the commonest cause of diabetes presenting in the first week of life. The majority of infants recover by 3 months of age but are predisposed to developing type 2 diabetes in later life. It is associated with low birth weight but rapid catch up by 1 year of life. The condition is usually due to genetic or epigenetic aberrations at an imprinted locus on chromosome 6q24 and can be sporadic or inherited. Early diagnosis alters medical treatment strategies and differentiates it from other types of early onset diabetes. In some individuals, diabetes may be the initial presentation of a more complex imprinting disorder due to recessive mutations in the gene ZFP57 and may be associated with other developmental problems<br/
SHIELD: A Novel NFV-based Cybersecurity Framework
No full textSHIELD is an EU-funded project, targeting at the design and development of a novel cybersecurity framework, which offers security-as-a-Service in an evolved telco environment. The SHIELD framework leverages NFV (Network Functions Virtualization) and SDN (Software-Defined Networking) for virtualization and dynamic placement of virtualised security appliances in the network (virtual Network Security Functions – vNSFs), Big Data analytics for real-time incident detection and mitigation, as well as attestation techniques for securing both the infrastructure and the services. This papers discusses key use cases and requirements for the SHIELD framework and presents a high-level architectural approach
Assorted Blue Cross, Blue Shield Buttons
No full textAssorted BCBS buttons: “I Respond Best to The Basic Principles” button, undated; Respect LGBT & Allies @ Florida Blue button, undated; All Of Us Helping Each Of Us button, undated; I Adopted a Winner Blue Cross and Blue Shield of Florida button, undated; I Gave. They Pedaled. Blue Cross and Blue Shield of Florida button, undated; I “Bee” a ‘SME’ BCBSF Y2K Subject Matter Expert button, circa 2000; I’m Taking a Closer Look BlueCross BlueShield of Florida button, undated, (3); Blue Cross Blue Shield Organization Survey 1992 button, circa 1992; Direct Sales +1 in ‘85 button, circa 1985; Florida Health PAC [Political Action Committee] Team ‘88 button, circa 1988; Democracy I’m Doing My Part Through Florida Health PAC [Political Action Committee] button, circa 1990https://digitalcommons.unf.edu/flablue_artifacts/1127/thumbnail.jp
Shield I, Shield II and Shield IV prevent phage infection.
No full textGrowth curves of E. coli MG1655 carrying empty pBAD18 (VC) or the same plasmid encoding (a) ShdA I (the sole component of the Shield I system), (b) the Shield II system or ShdA II only, (c) Shield IV or ShdA IV only, and (d) Shield III or ShdA III only. Strains were grown in LB medium supplemented with 0.2% L-arabinose and phages ϕSipho or ϕAlma were added at the start of the growth curve at a MOI = 1. Points show mean +/− SEM (n = 3 biological replicates).</p
- …
